EHA 2019

CLL

View all

0:58

Update on CAR-NK cell therapy work at MD Anderson

William Wierda • 13 Jun 2019

1:23

Update on ERIC’s CLL studies and initiatives

Paolo Ghia • 13 Jun 2019

Multiple Myeloma

View all

2:46

CAR-T treatment outcomes: MM real-world data

Yi Lin • 13 Jun 2019

5:40

Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd

Philippe Moreau • 14 Jun 2019

Press Brief Presentations

Watch the presentations featuring the latest results in hematology research.

Highlights include updates on Phase 3 trials such as CASSIOPEIA and BELLINI, a new double-targeting approach for sickle cell disease, and a strategy to overcome resistance in refractory lymphoma.

Lymphoma

View all

1:38

The UK treatment landscape of mantle cell lymphoma

Simon Rule • 14 Jun 2019

2:25

JULIET: CRS and neurotoxicity in DLBCL

David Maloney • 13 Jun 2019

AML

View all

10:40

Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?

Christopher Hourigan • 14 Jun 2019

1:12

Heterogeneity in refractory AML

Christopher Hourigan • 15 Jun 2019

ALL

View all

3:33

CAR T-cells for ALL

Ulrich Jäger • 13 Jun 2019

1:01

Blinatumomab for pediatric ALL

Sara Ghorashian • 15 Jun 2019

MRD

View all

1:25

The role of MRD in CLL

Peter Hillmen • 14 Jun 2019

10:24

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Kirsten Fischer • 14 Jun 2019

CML

View all

2:17

Current CML treatments: which TKI to choose?

Gianantonio Rosti • 13 Jun 2019

1:55

Long-term monitoring, adherence & endpoints in CML

Gianantonio Rosti • 13 Jun 2019

Sickle cell, PNH, ITP & more

View all

1:50

SAA treatment and QoL

Anita Hill • 13 Jun 2019

2:41

Advances in the treatment and prognosis of TTP

Paul Coppo • 13 Jun 2019

CLL

Multiple Myeloma

Press Brief Presentations

Lymphoma

AML

Late-Breaking Abstracts

ALL

MRD

CAR T-cell Data

CML

Sickle cell, PNH, ITP & more